Navigation Links
MBL Signs Non-Exclusive License With Envoy Therapeutics for Access to RIP-Chip Technology
Date:3/15/2011

WOBURN, Mass., March 15, 2011 /PRNewswire/ -- Medical & Biological Laboratories Co., Ltd., MBL, has signed a non-exclusive license with Envoy Therapeutics for access to MBL's patented RIP-Chip technology. As part of the license agreement, MBL will receive upfront payment, annual licensing fees and potential milestone payments. Envoy Therapeutics will utilize the RIP-Chip technology for the company's drug discovery and development.

MBL President Katsuhiko Nishida said, "We are pleased to enter into this agreement with Envoy, an innovative drug discovery company. This agreement provides Envoy a freedom-to-operate condition of our technology as well as a complementary approach to discover novel drug targets." President Nishida also lauded the scientific aspect of the agreement by stating, "RIP-Chip technology can provide additional information to their drug discovery pipelines regarding MOA and/or toxicological information of new drugs."  

RIP-Chip helps researchers understand the complex molecular networks involving genes, DNA, RNA, microRNA, proteins and RNA localization as mediated by specific binding proteins.  RIP-Chip technology is the only high-throughput approach for direct elucidation and analysis of these networks, whose importance has become increasingly clear with the growing appreciation for RNAi therapy, drug discovery and the role of RNA utilization in determining normal and disease outcomes.

About Medical & Biological Laboratories Co., Ltd.

Established in Nagoya, Japan, MBL was founded in 1969 as an antibody maker and is a leader in the development, manufacture, and distribution of antibodies and kits used in clinical diagnostics and life science research.  MBL Japan specializes in the business of diagnostic and research reagents as well as cytology products.  The MBL Network currently consists of 18 companies.  Additional information about MBL is available through its corporate website, www.mbl.co.jp.

About Envoy Therapeutics

Envoy Therapeutics's mission is to discover new drugs with superior efficacy and fewer side effects than existing treatments. The company's bacTRAP® technology enables the identification of proteins in vivo that are produced by specific cell types without requiring the isolation of those cells. The technology is especially powerful in tissues of the brain, where many hundreds of cell types are intermingled. Additional information about Envoy Therapeutics is available through its corporate website, www.envoytherapeutics.com.


'/>"/>
SOURCE Medical & Biological Laboratories Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
2. BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana
3. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
4. Assay Designs(TM), Inc. and the Spinal Muscular Atrophy Foundation Announce Collaboration To Accelerate the Discovery of New Therapeutics for Spinal Muscular Atrophy (SMA)
5. Martek Signs Multi-Year Sole-Source Supply Agreement With Hero
6. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
7. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
8. Huifeng Bio-Pharmaceutical (HFGB) Signs Exclusive Management Operating Agreement with Xian Qinba Xintong Medical Ltd.; HFGB to Retain Up to 70% of Qinbas Total Profit
9. Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards
10. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
11. StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 A new report published by ... Forecast, 2014-2022 ," the global market was valued at $6,769 million in 2015, ... 9.6% from 2016 to 2022. ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) The ...
(Date:4/19/2017)... WESTMINSTER, Colo. , April 19, ... industry-leading specialty finance firm that provides senior debt ... announced the closing of a $20 million senior ... privately-held orthobiologics company engaged in the development and ... treatment of orthopedic injuries. Cerapedics, lead ...
(Date:4/19/2017)... , April 19, 2017   Thermo Fisher ... the multi-center Procalcitonin MOnitoring SEpsis (MOSES) Study have ... of Critical Care Medicine . Researchers from ... Severe Sepsis Patients: Results From the Multicenter Procalcitonin ... the B·R·A·H·M·S PCT (procalcitonin) assay to assess risk ...
(Date:4/18/2017)... Jordan, Utah (PRWEB) , ... April 18, 2017 ... ... and collaboration company, has been awarded Channel Partners 2017 Next-Gen Solution Provider. , ... create business value for customers with their vision, innovation, and advocacy of the ...
Breaking Biology Technology:
(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
Breaking Biology News(10 mins):